|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SDHA |
Gene summary for SDHA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SDHA | Gene ID | 6389 |
| Gene name | succinate dehydrogenase complex flavoprotein subunit A | |
| Gene Alias | CMD1GG | |
| Cytomap | 5p15.33 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | P31040 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6389 | SDHA | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.40e-11 | 6.37e-01 | -0.1808 |
| 6389 | SDHA | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.27e-11 | 6.92e-01 | -0.0811 |
| 6389 | SDHA | HTA11_78_2000001011 | Human | Colorectum | AD | 2.89e-08 | 6.56e-01 | -0.1088 |
| 6389 | SDHA | HTA11_347_2000001011 | Human | Colorectum | AD | 3.30e-33 | 9.08e-01 | -0.1954 |
| 6389 | SDHA | HTA11_411_2000001011 | Human | Colorectum | SER | 3.10e-06 | 1.06e+00 | -0.2602 |
| 6389 | SDHA | HTA11_83_2000001011 | Human | Colorectum | SER | 3.27e-07 | 7.98e-01 | -0.1526 |
| 6389 | SDHA | HTA11_696_2000001011 | Human | Colorectum | AD | 2.49e-11 | 6.72e-01 | -0.1464 |
| 6389 | SDHA | HTA11_866_2000001011 | Human | Colorectum | AD | 2.03e-04 | 4.56e-01 | -0.1001 |
| 6389 | SDHA | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.19e-12 | 8.51e-01 | -0.059 |
| 6389 | SDHA | HTA11_2992_2000001011 | Human | Colorectum | SER | 7.51e-07 | 7.92e-01 | -0.1706 |
| 6389 | SDHA | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.94e-02 | 6.41e-01 | -0.2061 |
| 6389 | SDHA | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.20e-02 | 6.53e-01 | -0.1462 |
| 6389 | SDHA | HTA11_546_2000001011 | Human | Colorectum | AD | 1.94e-03 | 5.54e-01 | -0.0842 |
| 6389 | SDHA | HTA11_866_3004761011 | Human | Colorectum | AD | 3.79e-04 | 4.14e-01 | 0.096 |
| 6389 | SDHA | A002-C-010 | Human | Colorectum | FAP | 4.15e-02 | -1.29e-01 | 0.242 |
| 6389 | SDHA | A015-C-203 | Human | Colorectum | FAP | 5.90e-14 | -2.63e-01 | -0.1294 |
| 6389 | SDHA | A002-C-201 | Human | Colorectum | FAP | 1.43e-05 | -2.39e-01 | 0.0324 |
| 6389 | SDHA | A002-C-203 | Human | Colorectum | FAP | 4.98e-03 | -1.62e-01 | 0.2786 |
| 6389 | SDHA | A001-C-119 | Human | Colorectum | FAP | 7.47e-05 | -3.75e-01 | -0.1557 |
| 6389 | SDHA | A001-C-108 | Human | Colorectum | FAP | 1.80e-08 | -2.02e-01 | -0.0272 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0046034 | Colorectum | AD | ATP metabolic process | 142/3918 | 277/18723 | 2.64e-29 | 8.26e-26 | 142 |
| GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
| GO:0009060 | Colorectum | AD | aerobic respiration | 108/3918 | 189/18723 | 9.14e-28 | 1.43e-24 | 108 |
| GO:0045333 | Colorectum | AD | cellular respiration | 119/3918 | 230/18723 | 3.21e-25 | 4.02e-22 | 119 |
| GO:0006119 | Colorectum | AD | oxidative phosphorylation | 83/3918 | 141/18723 | 7.95e-23 | 8.30e-20 | 83 |
| GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
| GO:0022900 | Colorectum | AD | electron transport chain | 89/3918 | 175/18723 | 1.42e-18 | 8.91e-16 | 89 |
| GO:0019646 | Colorectum | AD | aerobic electron transport chain | 53/3918 | 87/18723 | 5.58e-16 | 2.16e-13 | 53 |
| GO:0042773 | Colorectum | AD | ATP synthesis coupled electron transport | 56/3918 | 95/18723 | 6.76e-16 | 2.22e-13 | 56 |
| GO:0042775 | Colorectum | AD | mitochondrial ATP synthesis coupled electron transport | 56/3918 | 95/18723 | 6.76e-16 | 2.22e-13 | 56 |
| GO:0022904 | Colorectum | AD | respiratory electron transport chain | 63/3918 | 114/18723 | 8.23e-16 | 2.45e-13 | 63 |
| GO:0033108 | Colorectum | AD | mitochondrial respiratory chain complex assembly | 46/3918 | 93/18723 | 8.95e-10 | 6.91e-08 | 46 |
| GO:0006099 | Colorectum | AD | tricarboxylic acid cycle | 19/3918 | 30/18723 | 5.82e-07 | 2.09e-05 | 19 |
| GO:0030111 | Colorectum | AD | regulation of Wnt signaling pathway | 102/3918 | 328/18723 | 8.51e-06 | 2.03e-04 | 102 |
| GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0019318 | Colorectum | AD | hexose metabolic process | 77/3918 | 237/18723 | 1.96e-05 | 4.01e-04 | 77 |
| GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:0044262 | Colorectum | AD | cellular carbohydrate metabolic process | 87/3918 | 283/18723 | 6.00e-05 | 1.01e-03 | 87 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05020111 | Prostate | BPH | Prion disease | 141/1718 | 273/8465 | 1.11e-31 | 1.23e-29 | 7.58e-30 | 141 |
| hsa05016111 | Prostate | BPH | Huntington disease | 149/1718 | 306/8465 | 8.82e-30 | 7.27e-28 | 4.50e-28 | 149 |
| hsa00190111 | Prostate | BPH | Oxidative phosphorylation | 83/1718 | 134/8465 | 3.75e-26 | 2.48e-24 | 1.53e-24 | 83 |
| hsa05208113 | Prostate | BPH | Chemical carcinogenesis - reactive oxygen species | 114/1718 | 223/8465 | 3.05e-25 | 1.44e-23 | 8.91e-24 | 114 |
| hsa05010111 | Prostate | BPH | Alzheimer disease | 165/1718 | 384/8465 | 4.03e-25 | 1.66e-23 | 1.03e-23 | 165 |
| hsa05415112 | Prostate | BPH | Diabetic cardiomyopathy | 102/1718 | 203/8465 | 6.06e-22 | 2.00e-20 | 1.24e-20 | 102 |
| hsa05014111 | Prostate | BPH | Amyotrophic lateral sclerosis | 151/1718 | 364/8465 | 3.37e-21 | 1.01e-19 | 6.25e-20 | 151 |
| hsa04714112 | Prostate | BPH | Thermogenesis | 110/1718 | 232/8465 | 5.16e-21 | 1.42e-19 | 8.78e-20 | 110 |
| hsa04932111 | Prostate | BPH | Non-alcoholic fatty liver disease | 83/1718 | 155/8465 | 2.49e-20 | 6.32e-19 | 3.91e-19 | 83 |
| hsa05022111 | Prostate | BPH | Pathways of neurodegeneration - multiple diseases | 180/1718 | 476/8465 | 7.70e-20 | 1.81e-18 | 1.12e-18 | 180 |
| hsa0501229 | Prostate | Tumor | Parkinson disease | 144/1791 | 266/8465 | 3.33e-33 | 1.10e-30 | 6.83e-31 | 144 |
| hsa0502027 | Prostate | Tumor | Prion disease | 142/1791 | 273/8465 | 2.80e-30 | 3.09e-28 | 1.92e-28 | 142 |
| hsa0501627 | Prostate | Tumor | Huntington disease | 150/1791 | 306/8465 | 2.72e-28 | 2.25e-26 | 1.40e-26 | 150 |
| hsa0501027 | Prostate | Tumor | Alzheimer disease | 166/1791 | 384/8465 | 1.64e-23 | 6.79e-22 | 4.21e-22 | 166 |
| hsa0501427 | Prostate | Tumor | Amyotrophic lateral sclerosis | 155/1791 | 364/8465 | 3.41e-21 | 1.13e-19 | 6.99e-20 | 155 |
| hsa0502227 | Prostate | Tumor | Pathways of neurodegeneration - multiple diseases | 182/1791 | 476/8465 | 1.34e-18 | 3.16e-17 | 1.96e-17 | 182 |
| hsa0501237 | Prostate | Tumor | Parkinson disease | 144/1791 | 266/8465 | 3.33e-33 | 1.10e-30 | 6.83e-31 | 144 |
| hsa0502036 | Prostate | Tumor | Prion disease | 142/1791 | 273/8465 | 2.80e-30 | 3.09e-28 | 1.92e-28 | 142 |
| hsa0501636 | Prostate | Tumor | Huntington disease | 150/1791 | 306/8465 | 2.72e-28 | 2.25e-26 | 1.40e-26 | 150 |
| hsa0501036 | Prostate | Tumor | Alzheimer disease | 166/1791 | 384/8465 | 1.64e-23 | 6.79e-22 | 4.21e-22 | 166 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SDHA | SNV | Missense_Mutation | novel | c.145G>A | p.Asp49Asn | p.D49N | P31040 | protein_coding | tolerated_low_confidence(0.27) | benign(0) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| SDHA | SNV | Missense_Mutation | rs370690436 | c.1352G>A | p.Arg451His | p.R451H | P31040 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR |
| SDHA | insertion | Frame_Shift_Ins | novel | c.1029_1030insCCAAAGAACCAGACCTGTGTCTTCTCTT | p.Ser344ProfsTer26 | p.S344Pfs*26 | P31040 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SDHA | insertion | In_Frame_Ins | novel | c.1193_1194insATCCCAGCACTTTGGGAGGCTGAA | p.Glu398_Pro399insSerGlnHisPheGlyArgLeuLys | p.E398_P399insSQHFGRLK | P31040 | protein_coding | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| SDHA | SNV | Missense_Mutation | rs375576259 | c.442G>A | p.Ala148Thr | p.A148T | P31040 | protein_coding | tolerated_low_confidence(0.47) | benign(0.057) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SDHA | SNV | Missense_Mutation | novel | c.1397C>T | p.Ala466Val | p.A466V | P31040 | protein_coding | deleterious_low_confidence(0.01) | benign(0.069) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SDHA | SNV | Missense_Mutation | c.178N>T | p.His60Tyr | p.H60Y | P31040 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.993) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| SDHA | SNV | Missense_Mutation | c.1144N>C | p.Gly382Arg | p.G382R | P31040 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
| SDHA | SNV | Missense_Mutation | rs199615452 | c.251N>A | p.Gly84Glu | p.G84E | P31040 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SDHA | SNV | Missense_Mutation | c.485N>C | p.Arg162Thr | p.R162T | P31040 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-IR-A3LF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |